Similarly, mRNA vaccines encoding MUC1-hemagglutinin (HA) Tag in LCP nanoparticles have demonstrated successful expression in 4T1 cells and lymph nodes, augmenting tumor-infiltrating CD8+ T-cells and reducing tumor size when combined with anti-CTLA-4 in mouse models. Here, CD8A is linked to neoplasm.